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Abstract
Psoriasis is characterized by hyperplasia of the epidermis and infiltration of leukocytes into both the dermis and epidermis.
IL-23, a key cytokine that induces TH17 cells, has been found to play a critical role in the pathogenesis of psoriasis. Apilimod
is a small-molecule compound that selectively suppresses synthesis of IL-12 and IL-23. An open-label clinical study of oral
administration of apilimod was conducted in patients with psoriasis. Substantial improvements in histology and clinical
measurements were observed in patients receiving 70mg QD. The expression of IL-23p19 and IL-12/IL-23p40 in skin lesions
was significantly reduced in this dose group, with a simultaneous increase in IL-10 observed. A decrease in the levels of TH1
and TH17 cytokines/chemokines in skin lesions followed these p19 and p40 changes. In parallel, a reduction in skin-
infiltrating CD11c
+ dendritic cells and CD3
+ T cells was seen, with a greater decrease in the CD11c
+ population. This was
accompanied by increases in T and B cells, and decreases in neutrophils and eosinophils in the periphery. This study
demonstrates the immunomodulatory activity of apilimod and provides clinical evidence supporting the inhibition of IL-12/
IL-23 synthesis for the treatment of TH1- and TH17-mediated inflammatory diseases.
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Introduction
Psoriasis vulgaris is one of the most prevalent cell-mediated
inflammatory diseases in humans [1] and serves as a model in
which the activity and immune mechanisms of new therapeutics
can be readily evaluated in affected tissues. Recent data from
inflammatory skin models suggests that IL-23 and TH17 T cells,
which produce IL-17 and IL-22, could be key inducers of
epidermal hyperplasia and altered epidermal differentiation in
psoriasis [2,3]. This pathway is implicated by a marked increase in
IL-23 synthesis [4] and TH17 T cells are found in psoriasis lesions
[5,6]. Genetic study has demonstrated the association of the IL-
23/Th17 pathway with susceptibility to psoriasis [7]. A decrease in
expression of p19 and p40 mRNAs (encoding IL-23) was observed
in patients responding to some immune-modulating treatments
[8,9]. Clinically significant efficacy in the treatment of moderate to
severe chronic plaque psoriasis was recently demonstrated by
ustekinumab (CNTO-1275) and briakinumab (ABT-874), which
both target the common p40 subunit of IL-12 and IL-23,
confirming the major role of IL-12 and IL-23 in the pathophys-
iology of the disease [10,11,12,13,14]. Another newly recognized
feature of psoriasis is that skin lesions are highly infiltrated by
CD11c
+ dendritic cells termed TIP-DCs (TNF- and iNOS-
producing DCs), which also synthesize IL-20 and IL-23 in skin
lesions [4,15,16]. Hence psoriasis brings together inflammatory
pathways driven by CD11c
+ DCs, TH1, and TH17 T cells, but in
the context of an accessible human organ in which effective
suppression of inflammation can fully reverse disease-defining
pathology and restore normal cell growth and gene expression
[17].
Successful clinical trials with antibodies directed against IL-12/
IL-23 support the approach of modulating inflammation in
psoriasis or other T cell mediated diseases by selectively blocking
production of IL-12 and IL-23. Although antibodies can provide
medical benefit, an orally available small-molecule IL-12/IL-23
inhibitor is also highly desirable. Apilimod (formerly STA-5326) is
a small molecule that was developed from a novel triazine
derivative identified through high-throughput IL-12 inhibitor
screening [18]. Apilimod effectively suppresses synthesis of IL-12
and IL-23 in myeloid leukocytes and oral administration of
apilimod led to a suppression of the TH1 but not TH2 immune
response in mice [18]. In vivo studies demonstrated that oral
administration of apilimod markedly reduced inflammatory
histopathologic changes. A striking decrease in IFN-c production
was observed in ex vivo culture of cells harvested from animals
treated with apilimod, indicating a down-regulation of the TH1
response by this compound.
In this study, patients with stable psoriasis vulgaris skin plaques
were treated orally with a range of apilimod doses. Skin biopsies
and whole blood were collected throughout a 12-week treatment
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PCR, cytometry, and cytokine production levels in ex vivo cell
culture, to measure inhibition of p40 cytokines and downstream
products in the local site of inflammation as well as in the
periphery. Our results establish that apilimod not only suppresses
synthesis of IL-12, IL-23, and multiple downstream cytokines in
the lesional skin, but also concomitantly increases synthesis of the
anti-inflammatory cytokine IL-10. This study also presents an
overall view of the action of this IL-12/IL-23 blocker, and
provides additional evidence for critical links between IL-23
synthesis, production of IL-17 at elevated levels in psoriasis, and
resulting histopathological alterations in the skin.
Results
Apilimod Treatment of Human whole Blood In Vitro
Leads to a Concurrent Decrease of IL-12 and Increase of
IL-10 and GM-CSF
It was previously reported that apilimod treatment inhibited IL-
12 production in human PBMCs, monocytes, monocyte-derived
dendritic cells, and the human monocytic cell line THP-1 with
IC50 values below 20nM, while not significantly suppressing the
production of other cytokines [18]. The selectivity of the
compound was further evaluated using SAC-stimulated human
whole blood. In this assay IL-12 production was consistently
inhibited by apilimod with the IC50 ranging from 20 to 200nM
(Fig. 1). Interestingly, IL-10 and GM-CSF production was
reproducibly enhanced by the compound (Fig. 1). The increase
of IL-10 and GM-CSF was dose-dependent and reached greater
than 2-fold at drug concentrations above 200 nM. IL-6 produc-
tion was neglibly affected in this assay.
DecreasedIL-12andIncreasedIL-10andGM-CSFinExVivo
Stimulated wholeBlood Cells Drawn 2h Post Oral
Administrationof Apilimod
Apilimod was tested in a Phase 2a multi-center, open-label
clinical trial in psoriasis patients in which the focus was a variety
of biomarker-based measures of biological response. Patients with
moderate to severe chronic plaque psoriasis received apilimod at
doses of 21mg BID, 35mg QD, 35mg BID, or 70mg QD orally
for 12 weeks. First, to confirm that the potency and selectivity of
apilimod was similar to the in vitro results above, whole blood was
collected pre- and 2 h post-dose to measure cytokine production
in response to ex vivo SAC stimulation. The 2 h time point
represents the approximate time at which the maximum
apilimod concentration in plasma was observed (mean 6 SD
plasma levels at 2 h post-dose were 41 6 41nM (n = 16), 122 6
82nM (n = 16), 115 6 60nM (n = 14), and 265 6 183nM (n =
15) at the doses of 21mg BID, 35mg QD, 35mg BID, and 70mg
QD, respectively). Figure 2 shows the changes in cytokine
production levels in the ex vivo culture with the whole blood
containing orally absorbed apilimod from the patients receiving
the highest dose of 70mg. IL-12 production was decreased at 2 h
post-dose compared to the pre-dose samples in several patients in
the dose group (median change of -27%), while GM-CSF and
IL-10 were concurrently increased (median change of +147%
and +71%, respectively). A decrease in IL-12 compared to the
corresponding pre-dose whole blood was also consistently
observed in the other dose groups (data not shown). GM-CSF
and IL-10 were also increased in the 35 mg apilimod cohort
(both QD and BID), but not 21 mg. This is in agreement with
the in vitro increases of these cytokines at a relatively high drug
concentration compared to the concentration which caused a
reduction in IL-12. The changes in cytokine production were not
correlated with patient response, indicating that this ex vivo assay
of peripheral blood at the apilimod Cmax is not sufficient to
predict clinical response.
Clinical Response to Apilimod Treatment
The primary efficacy endpoint of this biomarker study was the
proportion of patients with an improvement in the histological
assessment of skin biopsies. Frozen skin biopsies from non-lesion
skin and psoriatic lesions were analyzed for routine histopathology,
expression of keratin 16 (K16) and IL-12/IL-23p40, and numbers
of CD3
+ T and CD11c
+ dendritic cells. Given the typical
histopathology of baseline psoriasis, the grading system for the
histological assessment of epidermal hyperplasia is: (1) not
improved; (2) good improvement (reduction in hyperplasia and
normalized differentiation, but most suprabasal keratinocytes still
express K16); or (3) excellent improvement (reduction in
hyperplasia, normalized differentiation, absent K16 expression
or small foci of residual keratin expression). Patients with good or
excellent improvement at week 12 were considered responders.
Any patient missing data at week 12 was treated as a non-
responder. Figure 3 shows a representative example of a responder
who achieved excellent improvement. Overall clinical responses
based on histological assessment of skin biopsies and other clinical
measures in the four dose groups are shown in Table 1. There was
a clear trend towards better clinical outcomes at the dose of 70 mg
QD with half of patients showing significant histological
improvement at week 12. Comparisons between dose groups in
the clinical measures of PASI (Psoriasis Area and Severity Index)
and sPGA (static Physician’s Global Assessment) also favored the
70mg QD cohort. Similar to the histological improvement, around
half of patients achieved a 50% improvement in their PASI scores
and showed a 2-point or greater improvement in PGA from week
0 to week 12 in this dose group (Table 1). Overall, 13 of 15 total
patients with less than 30% reduction in PASI score at week 12
were defined as non-responders in histological assessment, and 9
patients with at least a 70% reduction in PASI score were all
histological responders, indicating a close correlation between the
histological assessment and the clinical measures.
Infiltrating T Cells and Dendritic Cells Post-apilimod
Treatment
Immunohistochemisty of skin lesions demonstrated that the
histological improvement was paralleled by progressive decreases
in the number of infiltrating CD3
+ (a marker of T cells) and
CD11c
+ (a marker of dendritic cells) cells (Fig. 3, Table 2). The
number of CD3
+ cells in both the epidermis and dermis was
decreased at week 12 from baseline in histological responders
(mean change 6 SD: 246 6 47% and 238 6 49%, respectively),
while no change was seen in non-responders (+5 6 78% and +10
6 69%, respectively). A dramatic decrease was seen in the number
of CD11c
+ cells in the responders (278 6 36% in epidermis and
252 6 39% in dermis), while the decrease in non-responders was
not significant (221 6 69% in epidermis and 22 6 59% in
dermis). The differences between responders and non-responders
at week 12 were statistically significant for CD3
+ cells and CD11c
+
cells in both the epidermis and dermis (Table 2). Among the dose
groups, the decreases in the infiltrating cells was most prominent in
the 70mg QD cohort (n = 12) for all of dermal CD3
+ (229%),
epidermal CD3
+ (231%), dermal CD11c
+ (229%), and epidermal
CD11c
+ (243%) cells at week 12. Within the 70mg QD dose
group, the largest decrease was observed in epidermal CD11c
+
cells with almost complete clearance in all responders (296 6 8%)
(Fig. 4).
Activity of Apilimod in Psoriasis
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35069Figure 1. In vitro effect of apilimod on IL-12p70, IL-10, GM-CSF, and IL-6 in human whole blood cells. Human whole blood from a normal
volunteer was stimulated with 0.1% SAC in the presence of different concentrations of apilimod. Supernatants were tested for IL-12p70 (circles), IL-10
(triangles), GM-CSF (diamonds) and IL-6 (squares). Results are representative of one of three individual experiments with whole blood from different
volunteers each time.
doi:10.1371/journal.pone.0035069.g001
Figure 2. Ex vivo stimulation of whole blood drawn 2h post 70mg dose as compared to the pre-dose in cytokine production. Whole
blood drawn pre-dose and 2h post 70mg dose (n = 10) were stimulated with 0.1% SAC within 24h of the draw, and the supernatants were analyzed
for IL-12p70 (a), IL-10 (b), and GM-CSF (c). *, p #0.05; statistically significant differences between pre- and 2h post-dose.
doi:10.1371/journal.pone.0035069.g002
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To determine the in vivo effects of apilimod on the expression
of the target genes IL-12 and IL-23, as well as their downstream
targets at the local site of inflammation, we conducted RT-PCR
on skin biopsies collected before and after treatment. The level of
gene expression in each biopsy was normalized to human acidic
ribosomal phosphoprotein PO (hARP). This protein, whose
mRNA level is stable regardless of treatment, was used to
confirm the quality of the samples [19]. The level of IL-12/IL-
23p40 and IL-23p19 expression at baseline was remarkably
higher in psoriatic skin lesions (median normalized gene
expression of 51.3 and 38.0, respectively, n = 54) compared to
corresponding normal skin (0 and 7.9, respectively). Significant
decreases in p40 and p19 at week 2 from baseline were
demonstrated in the 70mg QD group with median percent
changes of 265% and 245%, respectively (Fig. 5). In contrast,
IL-10 was increased with a +98% median percent change
relative to the baseline (n = 9) (Fig. 5). Two patients (1035 and
1046) excluded in the analysis of the percent change in IL-10 (as
the baseline value was 0) also showed a dramatic increase in IL-
10 (23 and 59 from 0). The IL-10 decrease seen in patient 1045
was accompanied by a decrease in epidermal CD11c
+ cells at
week 2, suggesting that decreased IL-10 was likely due to the loss
of IL-10 producing cells in the epidermis, still consistent with
increased IL-10 expression by apilimod treatment when no
change in the infiltrating cell population is apparent.
At week 12, the gene expression of IL-12/IL-23p40 and IL-
23p19 was further reduced from baseline in the 70mg QD
group (median changes of 274% and 281%, respectively, n =
7). IL-10 gene expression remained higher than the baseline in
the dose group (+141%, n = 5). As predicted from the
biological effects of IL-12/IL-23, one would expect inhibition of
the downstream T cell and inflammatory pathways affected by
IL12/IL-23 follows inhibition of these cytokines. Consistent with
this view, a marked reduction in the gene expression of K16,
iNOS, IL-8, IL-17, TNF-a, and IFN-c was observed at week 12
(median changes of 251%, 258%, 261%, 223%, 243%, and
250%, respectively, n = 7) while only small and inconsistent
decreases were seen at week 2. Moreover, a nearly complete
reduction in K16 and TH1/TH17 cytokines and chemokines
was demonstrated in most of histological responders with the
median gene expressions at week 12 comparable to the levels of
non-lesional skin (Fig. 6). In contrast, no significant changes
were seen in non-responders.
Effect of Apilimod Treatment on Peripheral Cell Profile
It is known that peripheral immune cells are recruited to sites
of local inflammation [20,21,22]. To determine the effect of
apilimod on the trafficking of immune cells, whole blood
samples from patients were analyzed for immune cell profiling
side-by-side with samples from normal controls. Neutrophil,
eosinophil, and monocyte counts (mean 6 SD cells/mL) at
baseline were significantly higher in psoriasis patients than in
normal controls (4476 6 1699 vs. 3066 6 947; p = 0.001, 231
6 152 vs. 138 6 102; p = 0.008, 420 6 128 vs. 316 6 123; p
= 0.004, n = 60 and 16, respectively). In contrast, CD4
+ T cell
counts were slightly lower in psoriasis patients than in controls
(742 6 276 vs. 843 6 283; p = 0.125). There was no
significant difference in CD8
+ T and B cell counts between
psoriasis patients and normal controls (354 6 168 vs. 367 6
135; p = 0.679 and 220 6 138 vs. 225 6 78; p = 0.200,
respectively). After 12 weeks of treatment with apilimod,
neutrophil and eosinophil counts were decreased in the 70mg
QD cohort, while the counts of CD4
+ T, CD8
+ T, and B cells
were significantly increased (Fig. 7). The increase of CD4
+ T,
CD8
+ T, and B cells is more pronounced when expressed as a
percentage of whole blood cells (mean change 6 SD: +33 6
Figure 3. Histological improvement by apilimod treatment.
Histology and immunohistochemistry of one patient (1046) showing
improved histology and clinical measures (58% reduction in PASI score)
at week 12 in the 70mg QD apilimod treated group. Skin biopsies from
non-lesions (left) and lesions (middle) at baseline and lesion at week 12
(right) were stained with H&E, K16, anti-CD3 Ab, anti-CD11c Ab, or anti-
IL-12p40 Ab. Cells staining positive for CD3, CD11c and IL-12p40 are
indicated (arrows).
doi:10.1371/journal.pone.0035069.g003
Table 1. Clinical response based on assessment of skin
biopsies and PASI and PGA.
21 mg BID
n=17
n( % )
35 mg QD
n=17
n( % )
35 mg BID
n=16
n( % )
70 mg QD
n=15
n( % )
Histological
Improvement
3 (18) 4 (24) 3 (19) 7 (47)
PGA Clear/
Almost Clear
1 (6) 1 (6) 1 (6) 2 (13)
PASI 75 0 0 1 (6) 2 (13)
Mean Improvement
in PASI
15% 29% 40% 46%
PASI 50 3 (18) 5 (29) 8 (50) 7 (47)
2 pt Improvement
in PGA
3 (18) 4 (24) 5 (31) 8 (53)
doi:10.1371/journal.pone.0035069.t001
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= 0.0005, respectively). These results indicate that apilimod
treatment resulted in a shift toward the normal state. There was
no significant change in the monocyte counts (Fig. 7) or
percentage (+4 6 21%, p = 0.622) after apilimod treatment.
Similar increases in peripheral CD4
+ T, CD8
+ T, and B cells,
and a decrease in neutrophils after treatment with apilimod
were also observed in histological responders (mean change 6
SD in the percentage: +34 6 58%, +33 6 44%, +41 6 53%,
and 26 6 13%, n = 15), although the difference from non-
responders (+13 6 24%, +15 6 28%, +25 6 38%, and 21 6
9%, n = 28) did not achieve statistical significance in any
cellular subset.
Discussion
Apilimod is an orally available small molecule that selectively
and potently inhibits IL-12 and IL-23 production. The IL-12 p35
and p40 promoter driven luciferase assay indicated that the
compound inhibits transcription of both p35 and p40 genes [18].
Investigation of regulatory factors revealed that nuclear accumu-
lation of c-Rel, but not other NF-kB family member p65 or p50,
was impaired by apilimod (Y. Wada, unpublished data). It was
recently shown that c-Rel specifically regulates expression of IL-
12p35, IL-12/IL-23p40, and IL-23p19 [23,24,25,26]. The
findings adequately explain the selective inhibition of these genes
by apilimod. Upregulated expression of c-Rel has been shown in
Figure 4. Changes in epidermal CD11c
+ cells in responders and non-responders in 70mg QD apilimod cohort. Results shown are the
number of epidermal CD11c
+ cells in individual patients categorized as either responders (left, n = 7) or non-responders (right, n = 7) in the 70mg
QD cohort at baseline (week 0), week 2, 6, and 12.
doi:10.1371/journal.pone.0035069.g004
Table 2. Mean skin-infiltrating T cell and dendritic cell numbers.
Population
1 wk0 wk2 wk6 wk12
Epidermal CD3
+ cell Mean cell number non-responder 74 79 68 65
responder 68 63 44 25
p value between group 0.631 0.267 0.127 0.001
Dermal CD3
+ cell Mean cell number non-responder 112 112 95 109
responder 123 115 73 64
p value between group 0.464 0.889 0.177 0.008
Epidermal CD11c
+ cell Mean cell number non-responder 47 44 38 32
responder 40 41 20 8
p value between group 0.555 0.800 0.039 0.002
Dermal CD11c
+ cell Mean cell number non-responder 142 141 127 118
responder 140 154 93 56
p value between group 0.929 0.623 0.158 0.001
1Mean cell numbers of epidermal CD3
+ (T cell) cells, dermal CD3
+ cells, epidermal CD11c
+ (dendritic cell) cells, and dermal CD11c
+ cells per low-power field during
treatment, with patients classified by response. There were 17 responders and 30 non-responders in the analysis.
doi:10.1371/journal.pone.0035069.t002
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activity of apilimod in these populations.
An elevation of IL-12/IL-23p40 mRNA and protein levels as
well as IL-23p19 mRNA has been reported in psoriatic skin
lesions [4,27,28]. Here, we show a consistent decrease in p40
and p19 mRNA in psoriatic lesions as early as week 2 following
the initiation of apilimod treatment in the highest dose group.
There was no notable decrease in infiltrating cells at this early
Figure 6. Changes in the expression levels of TH1, TH17, and other inflammatory genes at week 12 in responders and non-
responders. RT-PCR was performed with biopsies obtained from non-lesion skin and psoriatic lesions. Results shown are the percentile range (25
th–
75
th%, medians indicated) of histological responders (n = 11) and non-responders (n = 27) for IL-12/IL-23p40, IL-23p19, K16, IL-8, IL-17, IFN-c, iNOS
and TNF-a. There were 26 non-responders for IL-17, and 10 responders and 23 non-responders for IL-10 in the analysis of the change due to 0 value at
baseline. *, p , 0.05; **, p ,0.01; statistically significant differences between before (week 0) and after (week 12) apilimod treatment in responder and
non-responder groups.
doi:10.1371/journal.pone.0035069.g006
Figure 5. Changes in the expression levels of IL-12/IL-23p40, IL-23p19, and IL-10 at week 2 in 70mg QD apilimod cohort. RNA was
prepared from biopsies obtained from the psoriatic skin lesions at baseline (week 0) and week 2, and RT-PCR was performed for IL-12/IL-23p40 (a), IL-
23p19 (b), and IL-10 (c). The expression levels were normalized to house keeping gene, hARP. Results shown are the expression levels of individuals in
70mg QD cohort (n = 11, 3 histological responders, 8 histological non-responders). *, p #0.05; **, p #0.01; statistically significant differences
between baseline and week 2.
doi:10.1371/journal.pone.0035069.g005
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effects of apilimod on cytokine expression in cells, and not a
result of changes in the cell number itself. At week 12, marked
reductions in the gene expression including TH1/TH17
cytokines and chemokines paralleled the clearance of infiltrating
cells in the responders, suggesting that mRNA reduction is
partially due to the loss of cytokine-producing cells. Since CD3
+
T cells were not totally cleared, the dramatic reductions in the
levels of TH1/TH17 genes are likely due to a selective clearance
of TH1/TH17 cells from the lesions and/or a marked
suppression of the gene expression as a consequence of the
clearance of IL-12/IL-23 producing CD11c
+ cells. Importantly,
clinical response correlated with the suppression of TH1/TH17
and downstream genes at week 12, validating the relevance of
targeting this pathway for disease improvement.
In this study, a near-complete clearance of epidermal CD11c
+
cells from lesions was observed in the responders in the 70mg QD
group at week 12. A statistically significant reduction of CD3
+ T
cells in the responder group was also seen, however the reduction
in CD3
+ T cell numbers was less than the reduction of CD11c
+
cells in both the epidermis and dermis. It is noteworthy that
psoriasis clinical studies of ustekinumab [29], alefacept (CD2
binding portion LFA-3)[8], and etanercept (TNF-receptor fusion
protein)[9] all showed greater decreases in CD3
+ T cells compared
to CD11c
+ cells. A comparative reduction in CD3
+ T cells and
CD11c
+ cells was achieved in a clinical study of efalizumab (anti-
CD11a) [15]. The preferential reduction in CD11c
+ cells by
apilimod seen in the responders may be a consequence of its
primary effect on this population. Because a good correlation
between hyperplasia improvement and CD11c
+ cell numbers in
skin lesions has been consistently observed [8,9,15], clearance of
CD11c
+ cells is expected to result in faster resolution of psoriatic
lesions and may help achieve better clinical outcome in
combination with other agents that primarily target T cells.
Interestingly, we found that baseline levels of TNF-a and IFN-c
mRNA were higher in responders than non-responders (Fig. 6).
The difference in baseline TNF-a was also pronounced in 70mg
QD group (mean 6 SD: 198 6 108, n = 3 vs. 59 6 42, n = 7). A
similar correlation of TNF-a mRNA at baseline with response to
treatment was seen in the ustekinumab trial [29]. The consistent
observation of a correlation in two independent studies suggests
that when inhibiting IL-12/IL-23, baseline TNF-a level may
represent a potential molecular predictor of response.
IL-10 was reproducibly increased in in vitro culture following
apilimod treatment as well as in lesions and ex vivo culture of whole
blood cells following oral administration. No similar increase was
Figure 7. Cellular phenotype in normal controls and psoriasis patients before and after 70mg QD treatment. Whole blood cells
from normal controls and psoriasis patients were analyzed by cytometry for the cellular phenotype. Results shown are the percentile ranges based on
cell counts (cells/mL) of peripheral CD4
+ T cells, CD8
+ T cells, B cells, monocytes, eosinophils and neutrophils from normal controls (n = 16) and
psoriasis patients in 70mg QD cohort (n = 12) at baseline (week 0) and week 12. Plot: bottom line, 10
th%; bottom box, 25
th%; top box, 75
th%; top line,
90
th%. *, p , 0.05; **, p ,0.01; statistically significant differences between before (week 0) and after (week 12) 70mg QD apilimod treatment in
psoriasis patients.
doi:10.1371/journal.pone.0035069.g007
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IL-10 modulation is due to a direct effect of apilimod, not
secondary to the inhibition of IL-12/IL-23. A significant increase
in the expression of GM-CSF by apilimod was also seen in vitro and
ex vivo. Increased IL-10 and GM-CSF levels have been reported to
be beneficial in the treatment of inflammatory disease [30,31].
Clinical efficacy with IL-10 treatment in psoriasis patients was
reported, with immunohistologic improvement [32,33], as well as
lowered incidence of relapse and prolonged disease-free interval
[34]. Thus, the enhanced IL-10 effects of apilimod are expected to
add benefit to clinical outcome.
We investigated multiple dose groups in this study, and
identified the highest responses in the 70mg QD dose cohort for
both histological and clinical improvements. Despite the fact that
the range of apilimod doses in the four groups was narrow, the
difference between 70mg QD group and 21mg BID group was
apparent in gene expression of IL-23p19 in skin lesions at week 12
(281% vs. +20%, p = 0.192). The two doses are more distinct in
the Cmax than the total AUC and Ctrough. In addition, the 70mg
QD group demonstrated a better clinical response than the 35mg
BID group despite the similar AUC0–24h in the 70mg QD and the
35mg BID cohorts, suggesting that a sufficiently high drug plasma
concentration for a short duration rather than the total AUC
determines efficacy. As the IL-12/IL-23 producing CD11c
+ cells,
the target of apilimod, are localized in the inflamed skin [4], the
superior response of 70mg QD group implies that a higher drug
level may have been achieved and maintained in the skin layers at
this dose compared to others.
Ustekinumab has demonstrated great clinical success and has
been approved for psoriasis treatment. How does apilimod differ
from this antibody in terms of clinical response based on PASI 75?
In a dose-escalating study in which patients received an i.v.
infusion of 0.1, 0.3, 1, or 5 mg/kg of ustekinumab, significant
improvement was observed at the two highest dose levels [29].
However, the mean PASI reduction shown by a sub-optimal
0.3mg/kg dose of the antibody was approximately 50% at week 12
[29], similar to the mean PASI reduction achieved by the 70mg
QD apilimod dose. In addition, both ustekinumab and apilimod
demonstrated reduction of skin infiltrated CD11c
+ or CD3
+ cells
in responders with the reduction appearing slower for apilimod (6
weeks vs. 2 weeks for ustekinumab) [29]. It is reasonable to suggest,
therefore, that the lower therapeutic activity of apilimod is likely
due to insufficient drug levels to achieve an optimal clinical
response. In this regard apilimod dosing is limited to 70 mg BID as
CNS-related adverse events (headache, flushing, hypoesthesia,
dizziness and paresthesia) were observed at a 105 mg BID dose
level in a previous Phase I study (Y. Wada, unpublished data).
This report does however highlight the therapeutic promise of a
small molecule IL-12/IL-23 inhibitor. The clear dose-response
reduction in production/expression of IL-12/IL-23, number of
infiltratingimmunecells,aswellastheclinicalmeasuresofPASIand
PGA, implies that removing the dose-limiting toxicity with a
derivative of apilimod and increasing the dose might produce
improved clinical effects similar to the IL-12/IL-23 antibody.
Moreover, the pronounced effects on dendritic cells over T cells
andonIL-10production/expressionareuniquetoapilimodandmay
be biologically advantageous. In general, an orally available small
molecule provides superior convenience and cost effectiveness for
application,particularlyinachronicdiseasestatesuchaspsoriasis.In
lightofthesepotentialadvantagesoveranIL-12/IL-23antibodysuch
as ustekinumab, several apilimod derivatives with improved safety
and pharmacokinetics arecurrently under investigation.
Animportantconsiderationofourfindingsrelatestotheprolonged
therapeutic targeting of this pathway. Studies in mice deficient in c-
RelandIL-12demonstratedthattheyaredefectiveinTH1[35],and
have increased risk of infections for which TH1 and IL-12 are
protectivesuchasLeishmaniamajor[36,37],raisingaquestionforriskof
opportunistic infections by suppressing TH1 response. However, no
evidence of immune-suppression was noted in comprehensive
immune-toxicology evaluations of ustekinumab [38], supporting
potential of long-term treatment withIL-12/IL-23 modulators.
Insummary,herewehavedemonstratedtheimmunomodulatory
activity of apilimod through extensive biomarker studies conducted
inpatientswithmoderate-to-severepsoriasis,byanalyzingbothlocal
skin and peripheral blood samples using multiple methods in
comparison with normal controls. The results provide an overall
view of the action of apilimod. This novel agent suppressed the
expression of IL-12/IL-23 in skin lesions and simultaneously
enhanced IL-10. The expression of TH1 and TH17 cytokines/
chemokines was reduced, accompanied by clearance of CD11c
+
dendritic cells and CD3
+ T cells from the skin lesions. Blocking the
recruitmentofimmunecellstotheskinresultedinanincreaseoftheir
populations, and a decrease of granulocytes, in the periphery. This
studyclearlydemonstratestheactivityofthesmallmoleculeapilimod
inpsoriasispatientsandfurthersupportsthecriticalroleoftheIL-23/
TH17 pathwayin the etiology ofthis disease.
Materials and Methods
Reagents
Apilimod was synthesized by Synta Pharmaceuticals Corp.
(Lexington, MA).
Clinical and Non-clinical (Normal Control) Study Design
Patients with moderate to severe chronic plaque psoriasis were
enrolled in the multi-center, open-label, multiple oral dose
outpatient study of apilimod (Protocol No. 5326–05). Eligible
patients included men and women, age 18–70 years old, who had
stable chronic plaque psoriasis (diagnosed at least 6 months before
screening) and who had psoriasis affecting $ 10% of body surface
area. Patients received apilimod 21mg BID, 35mg QD, 35mg
BID, or 70mg QD orally for 12 weeks. Skin punch biopsies were
collected for analysis of immunohistochemistry and RT-PCR at
baseline (both non-lesional and lesional skin) and week 2, 6, and 12
(lesional). Whole blood was collected in sodium-heparin tubes for
ex vivo cytokine production immediately before the administration
and 2h post-dose on day 1, pre-dose on week 2 and 12. Whole
blood was also collected in EDTA tubes for cell phenotype analysis
pre-dose at baseline (week 0), week 2 and 12. Sixty-five patients
were enrolled, and 45 (69.2%) patients completed the study. The
per-protocol population consisted of 51 patients: 16, 11, 12, and
12 in the 35mg QD, 21mg BID, 35mg BID, and 70mg QD dose
groups, respectively. The biopsy specimens were divided into two
samples; one sample was frozen OCT media for immunohisto-
chemistry, and the other was snap frozen in liquid nitrogen for
RT-PCR. Both samples were stored at -70uC. Histological
improvement of epidermal hyperplasia was defined by epidermal
thickness, rete elongation, differentiation status of keratinocytes,
and expression of K16 [negative in normal epidermis [39]].
Clinical response was assessed using the Psoriasis Area and
Severity Index (PASI) and the static Physician’s Global Assessment
(sPGA).
As an untreated control for the evaluation of biologic response,
whole blood was collected independently from 18 normal
volunteers at Synta Pharmaceuticals for analysis of ex vivo cytokine
production and cell phenotype with the schedule matched with the
blood collection from patients.
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in compliance with the Declaration of Helsinki Protocols. Prior to
study initiation, Schulman Associates Institutional Review Board
approval (21 Code of Federal Regulations, Part 56; Cincinnati
OH) was obtained for the original protocol and amendments. All
patients provided written informed consent.
Immunohistochemistry
Tissue sections were stained with hematoxylin (Fisher) and eosin
(Shandon, Pittsburgh) and purified mouse anti-human mAbs to
K16 (Sigma), CD3 (Becton Dickinson), CD11c (BD Pharmingen)
and IL-12/IL-23p40 (R&D Systems). Biotin-labeled horse anti-
mouse antibody (Vector Laboratories) was detected with avidin–
biotin complex (Vector Laboratories) and developed with
chromogen 3-amino-9-ethylcarbazole (Sigma Aldrich). Epidermal
thickness measures were computed by using National Institutes of
Health software (NIH IMAGE 6.1), and positive cells were
counted using computer-assisted image analysis, as previously
described [40].
Analysis of Tissue mRNA Gene Expression
RNA was extracted from tissues frozen in liquid nitrogen by
using the RNeasy Mini Kit (Qiagen, Valencia, CA). The primers
and probes for TaqMan RT-PCR assays for K16, IFN-c, TNF-a,
iNOS, IL-8, IL-10, IL-17, IL-12/IL-23p40, and IL-23p19 were
generated with the PRIMER EXPRESS algorithm, version 1.0.
All primers and probes were purchased from Applied Biosystems.
The RT-PCR was performed with EZ PCR Core Reagents
(Applied Biosystems) according to the manufacturer’s directions.
The samples were amplified and quantified on an Applied
Biosystems PRISM 7700 by using the following thermal cycler
conditions: 2 min at 50uC; 30 min at 60uC; 5 min at 95uC; and 40
cycles of 15 sec at 95uC followed by 60 sec at 60uC. The human
acidic ribosomal phosphoprotein PO (hARP) gene, a housekeep-
ing gene, was used to normalize each sample and each gene. The
data were analyzed and quantified using the software provided
with the Applied Biosystems PRISM 7700 (SEQUENCE
DETECTION SYSTEMS, version 1.7). Skin biopsies that had
degraded RNA defined by , 500 hARP or showed irregular
mRNA amplification curves were excluded from the analysis [41].
In Vitro and Ex Vivo Stimulation of whole Blood Samples
for Cytokine Production
In vitro assay was conducted in the presence or absence of
apilimod prepared in DMSO with the final DMSO concentration
adjusted to 0.25% in all cultures, including the compound-free
control. Ex vivo assay was conducted with whole blood in collection
tube shipped at ambient temperature overnight from the clinical
sites. Within 24h of collection, whole blood was stimulated with
equal volumes of RPMI 1640 media containing a final
concentration of 0.1% of Staphylococcus aureus Cowan I (SAC)
(Calbiochem, La Jolla, CA) for 22–24h. The supernatants were
harvested on the next day, and analyzed for IL-12, IL-10, and
GM-CSF using Bio-Plex assays (Bio-Rad). In the ex vivo assay, the
level of IL-12 was also confirmed using high sensitivity Quantikine
ELISA Kit (R&D Systems).
Cellular Phenotyping
The protocol included 49 three-color cell surface assays
performed by microvolume laser scanning cytometry (MLSC) on
the SurroScan
TM system (Biomarker Discovery Sciences, PPD,
formerly SurroMed) [42,43]. Briefly, monoclonal antigen-specific
antibodies were purchased from various commercial vendors,
coupled to red emitting fluorophores and developed into cellular
assays. Phenotypes were determined based on the presence of the
following antigens: CD4
+, T cells; CD8
+, T cells; CD19
+/CD20
+,
B cells; CD14
+, monocytes; CD66b
+, eosinophils; CD16
+,
neutrophils. Staining began within 30 h of sample collection.
Aliquots of whole blood or red blood cell-lysed blood from EDTA
collection tubes were added to 96-well micro-titer plates
containing the appropriate reagent cocktails, incubated in the
dark at room temperature for 20min, diluted with an appropriate
buffer and loaded into Flex32
TM capillary arrays (PPD) and
analyzed with SurroScan
TM. Images were converted to a list-mode
data format with in-house software. Fluorescence intensities were
compensated for spectral overlap of the dyes so values are
proportional to antigen density. Standard template gates were
established using FlowJo
TM cytometry analysis software (Tree
Star, Inc., Ashland, OR) customized for PPD Biomarker/
SurroMed to enable upload of gates to our Oracle database.
Gating information was applied to the scan data for each assay to
generate the resulting cell count and antigen intensity data.
Statistical Analyses
The change over time in immunochemistry values was
compared between histological responders versus non-responders
using a two by four mixed analysis of variance (ANOVA) model
(Table 2). These time changes were compared across the four dose
groups using a four by four mixed ANOVA. Given the wide
variability in the data and the small sample sizes, it was
determined that a non-parametric approach was most suitable to
make these same comparisons for the RT-PCR data. To do this,
each variable was expressed as the difference from baseline as a
percent of baseline. These percent changes were then compared
across the four treatment groups using the Kruskal-Wallis one-way
analysis of variance by ranks. Comparison of these percent
changes between responders and non-responders was made using
the Wilcoxon Ranks Sums Test.
Comparison of the absolute changes in cytokines from baseline
to 2h post-dose within the 70mg QD group was made using the
Wilcoxon Signed Ranks test (Fig. 2). Changes in the gene
expression levels from baseline to week 2 in the 70mg QD group
were also compared using the Wilcoxon Signed Ranks test (Fig. 5).
This test was also used to compare changes in the gene expression
levels from baseline to week 12 for both responders and non-
responders (Fig. 6).
Statistical analyses for the cellular phenotyping considered the
following comparisons: 1) between psoriasis subjects and healthy
controls, 2) within group before and after drug treatment, and 3)
between histological responders and non-responders. For all
between group statistics, we applied a univariate mean comparison
test that was either parametric or non-parametric depending on
the normality of the data. Goodness-of-fit statistics (Shapiro-Wilk)
and tests of skewness and kurtosis are performed to assess
normality. If the data were approximately normally distributed
in both groups, the parametric statistic was used (t-test); if not, the
nonparametric rank test (Wilcoxon rank sum test) was applied. All
tests of hypotheses were two-sided. Paired two-group comparison
for normal controls and psoriasis subjects was designed to identify
differences associated with the drug, independent of clinical
outcome. The control comparisons were expected to not show
differences and provide a check on the level of false positives.
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